Content deleted Content added
Line 37:
On October 31, 2008, the FDA granted further approval to market Treanda for the treatment of indolent B-cell [[non-Hodgkin's lymphoma]] (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. <ref>{{cite web |url=http://www.cephalon.com/media/news-releases/article/video-cephalon-receives-fda-approval-for-treanda-to-treat-patients-with-relapsed-indolent-non-hodgk/ |title=Cephalon press release -Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma |accessdate=2008-11-03 |format= |work= }}</ref>
==Pharmacology==
Betamustine acts as an alkylating agent causing intra-strand and inter-strand cross-links between DNA bases.
After intravenous infusion it is extensively metabolised in the liver by cytochrome p450. >95% of the drug is bound to protein - primarily albumin. Only free bendamustine is active. Elimination is biphasic with a half-life of 6–10 minutes and a terminal half-life of approximately 30 minutes. It is eliminated primarily by the renal route.
==References==
{{Reflist}}
| |||